

## REFERENCES

1. Allison, H.; Bartlett, M. D. and Kristina, G. H. (2010). Concise Reviews of Pediatric Infectious Diseases, *J Infect Dis*, **29**: 860–861.
2. Arbique, I.; Forward, K.; Haldare, D.; Davidson, R. (2001). Comparison of the velogene MRSA ID system for rapid identification of methicillin resistant *Staphylococcus aureus*. *J Infect Dis*, **44**:5-10.
3. Arthur, M.; Reynold, P. E. and Depardieu, F. (1996). Mechanism of glycopeptides Resistance in Enterococci. *J Infect Dis*, **32**:11-16.
4. Assadullah, S.; Kakru, D. K.; Thoker, M. A.; Bhat, F. A.; Hussain, N. and Shah, A. (2003). Emergence of low level vancomycin resistance in MRSA. *Indian J Med Microbiol*, **21**:196-198.
5. Bannerman, T.; L. (2003). Staphylococci, *Micrococcus* and other catalase-positive cocci that grow aerobically. *J Am Soci Micrbiol*, **18**: 384-404.
6. Bataineh, A.; B. (2006). Resistance of *Staphylococcus aureus* to Vancomycin in Zarqa, Jordan. *Pak J Med Sci*, **22**:144-148.
7. Bettina, L.; Muzaffar, H.; Matthias, G.; Michaela, B.; Dirk, H.; Georg, V.; Johannes, R.; Barbara, C.; Kahl, R. A., and Georg, P. (2010). *Staphylococcus aureus* Panton-Valentine Leukocidin Is a Very Potent Cytotoxic Factor for Human Neutrophils, *PLoS Pathogens*, **6**:(1):715.
8. Bilal, N. E. and Gedebo, M. (2000). *Staphylococcus aureus* as a paradigm of persistent problem of bacterial multiple antibiotic resistance in Abha, Saudia Arabia. *J East Mediterr Health*, **6**:948-954.
9. Blake, J. E. and Metcalfe, M. A. (2001). A shared non-capsular antigen is responsible for false-positive reactions by *Staphylococcus epiderimidis* in commercial agglutination tests of *Staphylococcus aureus*. *J Clin Microbiol*, **22**: 39-50.

10. **Boyce, J. M.; Cookson, B.; Chirstiansen, K. H.; Vuopio, J.; Kocagoz, S. (2005).** Methicillin- resistant *Staphylococcus aureus*. *J Lancet Infect Di*, **5**:653-663.
11. **Brown, D. F.; David, J.; Edwards, P. M.; Hawakey, D. M.; Geffry, L.; Ridgway, K. J.; Micheal, W. D. (2005).** Guidelines for the labrotary diagnosis and susceptibility testing of methicillin-resistant *Staphylococcus aureus* (MRSA) *J Antimicrob Agents and Chemother*, **56**:1000-1018.
12. **Centers for Disease Control and Prevention, (2002).** Vancomycin Resistant *Staphylococcus aureus* –Pennsylvania, Morbid, Mortal, Weekly Rep. **51**:902.
13. **Clinical and laboratory standard institute (2006).** Performance standard for antimicrobial susceptibility testing 15<sup>th</sup> informational supplement, M100-505. Waquc, P. A.
14. **Collee, J. G.; Mackie, T. J.; McCartney, J E. (1996).** In Practical medical microbiology Churchill livingstone 14<sup>th</sup> edition, New York, USA. **2**: 236-237.
15. **Cui, L. X.; Murakami, H.; Kuwahara, A. k.; hanaki, H. and Hiramatsu, K. (2000).** Contribution of thickened cell wall and it is glutamine non mediate component to vancomycin resistance and expressed by *Staphylococcus aureus* Mu50. *J Antimirob Agents chemother*, **44**:(22):76-85.
16. **Cui, L. X.; Sato, M. K. and Murakami, H. (2003).** Cell wall thickening is a common feature of vancomycin resistance in *Staphylococcus aureus* . *J Clin microbiol*, **41**:5-14.
17. **Dezfulain, A.; Salehain, MT.; Amini, V.; Dabiri, H.; Azimirad, M.; Aslani, M. M.; and Fazel, I. (2010).** Coagulase Negative *Staphylococcus aureus* isolated from a diabetic foot ulcer. *Iran J Microbiol*; **2**(3):165-167.

18. **Eickhoff, T. C. (1972).** Therapy of staphylococcal infection. In: Cohen JO, ed. The Staphylococci. Wiley, New York, USA. pp. 517-541.
19. **Fatholahzadeh, B.; Emaneini, M.; Gilbert, G.; Udo, E.; Aligholi, M. and Modarressi, M. H. (2008).** Staphylococcal Cassette Chromosome *mecA* analysis and antimicrobial susceptibility pattern of Methicillin resistant *Staphylococcus aureus* isolates in Tehran, Iran. *J Micro Drug Resis*, **14** (3):217-222.
20. **Flower, V. G.; Miro, J. M.; Hoen, B. (2005).** *Staphylococcus aureus* endocarditis: consequence of medical progress. *JAMA*, **9**:3012-3021.
21. **Francia, M. V.; and Clewell, D. B. (2002).** Amplification of tetracycline resistance determinant of PAMAI in *Enterococcus faecalis* require a site specific recombination event involving relaxase. *J Clin Bacteriol*, **184**:5187-5193.
22. **Francis, J. S.; Doherty, M. L. (2005).** Sever community –onset pneumonia in healthy adult. Caused by methicillin –resistant *Staphylococcus aureus* Carrying Recombination event involving relaxase. *J Bacteriol*, **6**:187-193.
23. **Gilmore K. S; Michael G. D; Sham. F. (2001).** Methicillin-Resistance antimicrobials. New York 243-256.
24. **Greenwood, D.; Richard, C. B.; Slack.; Johnf, P. (2002).** Book of Medical Microbiology 16<sup>th</sup> edit, chapter 15, Churchill Livingstone, London, UK. 168-173.
25. **Grundmann, H.; Aires, S. M.; Boyce, J. (2006).** Emergence and resurgence of methicillin resistant *Staphylococcus aureus* as public health threat. *J Clin Microbiol*, **22**:874-885.
26. **Hanaki, H.; Labischinski, H.; Inaba, Y.; Kondo, N.; Murakami, H. and Hiramatsu, K. (1998)** Increase in glutaminenon-amidated muropeptides in the peptidoglycan of vancomycin-resistant *Staphylococcus aureus* strain Mu50. *J Antimicrob Agents Chemother* **42**: 315-320.

27. **Hara, C. M.; Weinstein, M. P.; Miller, J. M. (2003).** Manual and automated systems for detection and identification of microorganisms. Manual of clinical microbiology, 8<sup>th</sup> edition, 185-207.
28. **Hiramatsu, K. (2001).** Vancomycin-resistant *Staphylococcus aureus*: a new model of antibiotic resistance. *J Lancet Infect Dis*, **8**: 147-155.
29. **Holloway, K. (2000).** Antimicrobial resistance: The facts. *Essential Drug Monitor WHO* 2000, **28&29**:7-8.
30. **Holmes, A.; Ganner, M. S.; Pitt, T. L.; Cookson, B. D. and Kearns, A. M. (2005).** *Staphylococcus aureus* Isolates carrying Panton-Valentine Leucocidin gene in England and Wales : Frequency, Characterization and association with Clinical Diseases. *J Clin Microbiol*, **43** (5):84-90.
31. **Katayarna, Y. T. and Hiramatsu K. A. (2000).** New classes of genetic elements, staphylococcus cassette chromosome mec, encode methicillin resistance *Staphylococcus aureus*. *J Antimicrob Agents and Chemother*, **44**:1549-1555.
32. **Kobaayashi, N. M.; Alam, Y.; Nishimoto, S.; Urasawa, N.; Vehra, N. and Watanebbe, (2001).** Distribution of glycopeptides resistance genes in recent clinical isolates., of *Enterococcus faecalis*, *Enterococcus faecium* and *Enterococcus avium*. *J Epidemiol Infect*, **126**:197-204.
33. **Levi, K.; Bailey, and Bennett. (2003).** Evaluation of an isothermal signal amplification method for rapid detection of methicillin resistant *staphylococcus aureus* from patient- screening swabs. *J Clin microbial*, **41**: 3187-3191.
34. **Lowy, F. D. (1998).** *Staphylococcus aureus* infection, *New Eng J Med*, **339**:(8):32-520.
35. **Mackie, and McCartney, Practical medical microbiology 16<sup>th</sup> edition.** Edited by : Collee, J. G.; Fraser, A. G.; Marmion, B. P. and Simmons, A. (2002). Churchill Livingstone, New York, USA; 245-262.

36. **Marchese, A.; Balistreri, G.; Tonoli, E.; Debbia, E. A.; Schito, G. C. (2000).** Heterogeneous vancomycin resistance in methicillin-resistant *Staphylococcus aureus* strains isolated in a large Italian hospital. *J Clin Microbiol*, **38**:866-869.
37. **Miller, D. V.; Uradanta, A.; Weltan, S. and park, (2002).** Vancomycin resistant *Staphylococcus aureus*, Morbid mortal Weekly Rep. **51**:902.
38. **Morris, A.; Kellner, J. D.; Low, D. E. (1998).** The superbugs: evolution, dissemination and fitness. *Curr Opin Microbiol* **5**:524-529.
39. **Mugisa, D. B. (1988).** Medicine (surgery) dissertation on complication following laparotomy in Mulago hospital , Master of Medicine (surgery) dissertation . Makerere University , Department of surgery, 59-156.
40. **Murray, R. P.; Baron, E. J; Jorgenensen, J.; Rosenthal, S. K.; kobayshi, S. G.; H; Pfaller, A. M. (2007).** Manual of clinical Microbiology, 9<sup>th</sup> edit. Washington, DC:ASM Press 202-210.
41. **National Committee For Clinical Laboratory standards (2003).** Antimicrobial susceptibility test by dilution method for bacteria that grow aerobically: Approved standard. 6<sup>th</sup> edition. NCCL document M07-A6- NCCL: Waqac, P. A.
42. **Nimmo, G. R.; Bell, J. M.; Mitchell, D.; Gosbell, B.; Pearman, J. W.; Turidge, J. D. (2003).** Antimicrobial resistance in *Staphylococcus aureus* in Australian teaching hospital. *J Microb Drug Resist*, **9**:155-160.
43. **Noble, N. L.; Viraniz, Cree, R. G. (1992).** Co-transfer of vancomycin and other resistance genes from *Enterococcus faecalis* NCTC 12201 to *Staphylococcus aureus*. *J clinic microbiol*, **72**:8-195.
44. **Palazzo, I. C. V.; Araujo, M. L. C. and Darini, A. L. C. (2005).** First Report of Vancomycin-Resistant Staphylococci Isolated from Healthy Carriers in Brazil. *J Clin Microbiol*, **43**:179-185.

45. **Raster, R.; Alaghebandan, R.; Akhlaghi, L. (2005).** Burn wound infection and antimicrobial resistance in Tehran, Iran: an increasing problem. *Annals and Barn and Fire Disater*, **18**(2):68-71.
46. **Rosato, A. (2003).** *mecA*-*blaZ* corepressors in clinical *Staphylococcus aureus* isolates. *J Antimicrob Agents and Chemother*, **47**: 1460-1463.
47. **Rotun, S. S.; McMath, V.; Schoonmaker, D. J.; Maupin, P. S.; Tenover, F. C.; Hill, B. C. and Ackman, D. M. (1999).** *Staphylococcus aureus* with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. *J Emerg Infect Dis*, **5**:147-149.
48. **Scott, K. F. (2001).** Vancomycin Intermediate and Resistant *Staphylococcus aureus* : What the Infectious Disease Specialist Needs to know. *J Healthcare Epidemiol*, **32**:108-115.
49. **Showsh, S. D.; Boever, R. H.; Clewell, D. B. (2001).** Vancomycin resistance plasmid in *Enterococcus faecalis* that encodes sensitivity to a sex pheromone also produced by *Staphylococcus aureus*. *J Antimicrob Agents and Chemother*, **45**:2177-2178.
50. **Sievert, D. M.; Boulton, M. L.; Stoltman, G.; Johnson, D.; Stobierski, M. G.; Downes, F. P.; Somsel, P. A.; Rudrik, J. T. (2002).** *Staphylococcus aureus* resistant to vancomycin – United States, 2002. *MMWR*, **51**:565-567.
51. **Song, J.; Hiramatsu, K.; Suh, J. Y.; Ko, K. S.; Ito, T.; Kapi, M.; Kiem, S.; Kim, Y. S.; Oh, W. S.; Peck, K. R.; Lee, N. Y. (2004).** Emergence in Asian countries of *Staphylococcus aureus* with reduced susceptibility to vancomycin. *J Antimicrob Agents and Chemother* 2004, **48**:4926-4928.
52. **Steward, P. S. and Consterton, J. W. (2001).** Antibiotics resistance of bacteria in biofilms. *Pubmed-gov*, **358**(9276):8-135.
53. **Subhash, C. P. (2009).** Text book of microbiology, ch.23, pp.219.

54. **Tenover, F. C.; Gaynes, R. P.; Fischetti, V. A.; Novick, R. P.; Ferrtting, J. J.; Portony, D. A. and Rood, J. L. (2000).** The epidemiology of *Staphylococcus* infection in Gram positive pathogens, Washington Dc. *J Amer Soci Microbiol*, 414-421.
55. **Tenover, F.C.; Biddle, J.W. and Lancaster, M. V. (2001).** Increasing resistance to vancomycin and other glycopeptides in *Staphylococcus aureus*. *J Emerg Inf Dis*, 7:327-332.
56. **Timothy, F. (2008).** Textbook of medical microbiology *S. aureus*, 12:1-13.
57. **Tiwari, K. H. and Sen, R. M. (2006).** Emergence of vancomycin resistance *Staphylococcus aureus* from tertiary care hospital from northern part of India. *J BMC Infect Dis*, 6:156.
58. **Van, G. A.; Bes, M.; Etienne, J. (2001).** International multicenter evaluation of latex agglutination tests for identification of *Staphylococcus aureus*. *J Clin Microbial*. 39:86-89.
59. **Walsh, C. T. (1993)** Vancomycin resistance: decoding the molecular logic. *Science* 261:308-309.
60. **Wanees, A. (2010).** Revisiting methicillin resistant *Staphylococcus aureus* infections. *J Glob Infect Dis*. 2(1):49-56.
61. **Weigel, L. M.; Clewell, D. B.; Gill, S. R.; Clark, N. C.; McDougal, L. K.; Flannagan, S. E.; Kolonay, J. F.; Shetty, J.; Killgore, G. E. and Tenover, F. C. (2003).** Genetic analysis of a high-level vancomycin-resistant isolate of *Staphylococcus aureus*. Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. Pubmed. gov. 302(5650):1569-71.